Advertisement

Topics

Harbour BioMed Company Profile

18:44 EDT 24th June 2018 | BioPortfolio

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for cancer, with a focus on immuno-oncology, and immunological diseases. The company's discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For additional information, please visit http://www.harbourbiomed.com.


News Articles [83 Associated News Articles listed on BioPortfolio]

和铂医药完成A+轮融资,加速临床项目开发和公司业务发展

和铂医药今天宣布完成A+轮融资,以加速公司总体业务发展,尤其是公司已有临床阶段项目的开发。本轮融资由中国顶级的投资机构鼎晖投资领投...

Harbour BioMed Raises Additional Capital in Series A+

Harbour BioMed of Shanghai has completed a Series A+ round of unspecified size. The funding was led by CDH Investments, a China PE firm, and joined by existing investor Advantech Capital. In late 2016...

Harbour BioMed Teams Up with Wistar to Discover Novel mAbs

Harbour BioMed formed a strategic collaboration with Philadelphia's Wistar Institute to co-discover novel antibodies for cancer and infectious disease indications. The agreement combines Harbour BioMe...

BeiGene to Generate New mAbs Using Harbour BioMed's Mouse Platform

Beijing's BeiGene licensed multi-year rights to use Harbour BioMed's H2L2 transgenic mouse platform, which generates fully human therapeutic monoclonal antibodies. Harbour BioMed, a Shanghai company, ...

China's Harbour BioMed Mulls Global Licensing

The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in...   

Deals this week: Ultragenyx Pharmaceutical, Insmed, Harbour BioMed

US-based biopharmaceutical company Ultragenyx Pharmaceutical Inc has announced a public offering of shares of its common stock to raise $175m....Read More... The post Deals this week: Ultragenyx Pharm...

BeiGene, ImmunoChina on antibody deals with Harbour

Cancer company BeiGene acquired Harbour BioMed's H2L2 transgenic mouse platform, to be used in multiple programs over a perio -More- 

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies to BeiGene, Ltd. (NASD...

Drugs and Medications [0 Results]

None

PubMed Articles [82 Associated PubMed Articles listed on BioPortfolio]

Settling fluxes and ecotoxicological risk assessment of fine sedimentary metals in Tema Harbour (Ghana).

Sediment traps were deployed in the Tema Harbour to estimate the settling fluxes of silt-clay particles and associated metals (Fe, Mn, Pb, Cr, Cu, Zn, Ni, Hg, Sn and As) and characterise their potenti...

Mitochondrial DNA reveals secondary contact in Japanese harbour seals, the southernmost population in the western Pacific.

In this study, we used relatively large number of samples (n = 178) and control region of mtDNA (454bp) to clearify the divergence history of Japanese harbour seals (Phoca vitulina stejnegeri) and phy...

Plastic ingestion by harbour porpoises Phocoena phocoena in the Netherlands: Establishing a standardised method.

Stomach contents of harbour porpoises (Phocoena phocoena) collected in the Netherlands between 2003 and 2013 were inspected for the presence of plastic and other man-made litter. In 654 stomach sample...

Recovery of the New Zealand muricid dogwhelk Haustrum scobina from TBT-induced imposex.

Levels of imposex in the muricid dogwhelk Haustrum scobina (Quoy & Gaimard, 1833) were assessed in two major New Zealand ports between 2015 and 2017, 12+years after the banning of TBT-based antifoulin...

Corrigendum to "double sword role of EZH2 in leukemia" Biomed. Pharmacother. 98 (2018) 626-635.

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

Amendment of rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen to...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study

Gastric subepithelial masses might harbour gastrointestinal stromal tumors, which should get resected because of their malignant potential. To minimize the associated surgical trauma endos...

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis...

Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC Patients

The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST crit...

Companies [55 Associated Companies listed on BioPortfolio]

Harbour BioMed

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for cancer, with a focus on immuno-oncology, and immunological diseases. Th...

Biomed Pharmaceuticals

The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmun...

BioMed Central Ltd

BioMed Central is an independent publishing house committed to providing immediate open access to peer-reviewed biomedical researchAll original research articles published by BioMed Central are made f...

Harbour Point Capital

Harbour Point Capital (“HPC”) is an independent private equity firm specializing in healthcare investing. The co-founders of HPC have worked together for eight years ...

Biomed

Biomed AG wurde 1951 in Zürich gegründet und hat sich seither als Handelsunternehmen für pharmazeutische Produkte im Schweizer Markt etabliert. Biomed ist spezialisiert auf den Handel mit rezeptpfl...

More Information about "Harbour BioMed" on BioPortfolio

We have published hundreds of Harbour BioMed news stories on BioPortfolio along with dozens of Harbour BioMed Clinical Trials and PubMed Articles about Harbour BioMed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harbour BioMed Companies in our database. You can also find out about relevant Harbour BioMed Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record